---
document_datetime: 2025-12-02 06:08:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/topotecan-actavis.html
document_name: topotecan-actavis.html
version: success
processing_time: 0.1106358
conversion_datetime: 2025-12-29 20:06:58.918535
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Topotecan Actavis

[RSS](/en/individual-human-medicine.xml/65451)

##### Withdrawn

This medicine's authorisation has been withdrawn

topotecan Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 January 2019, the European Commission withdrew the marketing authorisation for Topotecan Actavis (topotecan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Actavis Group PTC ehf, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Topotecan Actavis was granted marketing authorisation in the EU on 24 July 2009 for treatment of small-cell lung cancer and carcinoma of the cervix. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. The product had not been marketed in the EU since 2017. Topotecan Actavis is a generic medicine of Hycamtin. There are other generic medicinal products of Hycamtin authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Topotecan Actavis is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Topotecan Actavis : EPAR - Summary for the public

English (EN) (513.42 KB - PDF)

**First published:** 26/08/2009

**Last updated:** 26/08/2009

[View](/en/documents/overview/topotecan-actavis-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-969)

български (BG) (627.03 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/bg/documents/overview/topotecan-actavis-epar-summary-public_bg.pdf)

español (ES) (475.85 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/es/documents/overview/topotecan-actavis-epar-summary-public_es.pdf)

čeština (CS) (597.2 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/cs/documents/overview/topotecan-actavis-epar-summary-public_cs.pdf)

dansk (DA) (474.76 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/da/documents/overview/topotecan-actavis-epar-summary-public_da.pdf)

Deutsch (DE) (475.54 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/de/documents/overview/topotecan-actavis-epar-summary-public_de.pdf)

eesti keel (ET) (474.32 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/et/documents/overview/topotecan-actavis-epar-summary-public_et.pdf)

ελληνικά (EL) (624.72 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/el/documents/overview/topotecan-actavis-epar-summary-public_el.pdf)

français (FR) (475.34 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/fr/documents/overview/topotecan-actavis-epar-summary-public_fr.pdf)

italiano (IT) (475.22 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/it/documents/overview/topotecan-actavis-epar-summary-public_it.pdf)

latviešu valoda (LV) (617.84 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/lv/documents/overview/topotecan-actavis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (581.37 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/lt/documents/overview/topotecan-actavis-epar-summary-public_lt.pdf)

magyar (HU) (589.88 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/hu/documents/overview/topotecan-actavis-epar-summary-public_hu.pdf)

Malti (MT) (601.69 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/mt/documents/overview/topotecan-actavis-epar-summary-public_mt.pdf)

Nederlands (NL) (475.23 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/nl/documents/overview/topotecan-actavis-epar-summary-public_nl.pdf)

polski (PL) (603.16 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/pl/documents/overview/topotecan-actavis-epar-summary-public_pl.pdf)

português (PT) (943.09 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/pt/documents/overview/topotecan-actavis-epar-summary-public_pt.pdf)

română (RO) (576.17 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/ro/documents/overview/topotecan-actavis-epar-summary-public_ro.pdf)

slovenčina (SK) (591.46 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/sk/documents/overview/topotecan-actavis-epar-summary-public_sk.pdf)

slovenščina (SL) (556.76 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/sl/documents/overview/topotecan-actavis-epar-summary-public_sl.pdf)

Suomi (FI) (474.72 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/fi/documents/overview/topotecan-actavis-epar-summary-public_fi.pdf)

svenska (SV) (474.5 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

26/08/2009

[View](/sv/documents/overview/topotecan-actavis-epar-summary-public_sv.pdf)

## Product information

Topotecan Actavis : EPAR - Product Information

English (EN) (748.67 KB - PDF)

**First published:** 26/08/2009

**Last updated:** 02/03/2015

[View](/en/documents/product-information/topotecan-actavis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-422)

български (BG) (904.45 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/bg/documents/product-information/topotecan-actavis-epar-product-information_bg.pdf)

español (ES) (648.97 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/es/documents/product-information/topotecan-actavis-epar-product-information_es.pdf)

čeština (CS) (760.03 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/cs/documents/product-information/topotecan-actavis-epar-product-information_cs.pdf)

dansk (DA) (604.57 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/da/documents/product-information/topotecan-actavis-epar-product-information_da.pdf)

Deutsch (DE) (629.02 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/de/documents/product-information/topotecan-actavis-epar-product-information_de.pdf)

eesti keel (ET) (616.17 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/et/documents/product-information/topotecan-actavis-epar-product-information_et.pdf)

ελληνικά (EL) (902.9 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/el/documents/product-information/topotecan-actavis-epar-product-information_el.pdf)

français (FR) (1.01 MB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/fr/documents/product-information/topotecan-actavis-epar-product-information_fr.pdf)

hrvatski (HR) (632.49 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/hr/documents/product-information/topotecan-actavis-epar-product-information_hr.pdf)

íslenska (IS) (619.72 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/is/documents/product-information/topotecan-actavis-epar-product-information_is.pdf)

italiano (IT) (810.01 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/it/documents/product-information/topotecan-actavis-epar-product-information_it.pdf)

latviešu valoda (LV) (771.45 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/lv/documents/product-information/topotecan-actavis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (741.54 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/lt/documents/product-information/topotecan-actavis-epar-product-information_lt.pdf)

magyar (HU) (910.06 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/hu/documents/product-information/topotecan-actavis-epar-product-information_hu.pdf)

Malti (MT) (747.27 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/mt/documents/product-information/topotecan-actavis-epar-product-information_mt.pdf)

Nederlands (NL) (627.6 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/nl/documents/product-information/topotecan-actavis-epar-product-information_nl.pdf)

norsk (NO) (615.2 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/no/documents/product-information/topotecan-actavis-epar-product-information_no.pdf)

polski (PL) (811.54 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/pl/documents/product-information/topotecan-actavis-epar-product-information_pl.pdf)

português (PT) (1.26 MB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/pt/documents/product-information/topotecan-actavis-epar-product-information_pt.pdf)

română (RO) (699.4 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/ro/documents/product-information/topotecan-actavis-epar-product-information_ro.pdf)

slovenčina (SK) (733.51 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/sk/documents/product-information/topotecan-actavis-epar-product-information_sk.pdf)

slovenščina (SL) (991.93 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/sl/documents/product-information/topotecan-actavis-epar-product-information_sl.pdf)

Suomi (FI) (1 MB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/fi/documents/product-information/topotecan-actavis-epar-product-information_fi.pdf)

svenska (SV) (606.96 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

02/03/2015

[View](/sv/documents/product-information/topotecan-actavis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0013 15/01/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Topotecan Actavis : EPAR - All Authorised presentations

English (EN) (476.61 KB - PDF)

**First published:** 26/08/2009

**Last updated:** 24/11/2011

[View](/en/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-636)

български (BG) (489.63 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/bg/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_bg.pdf)

español (ES) (466.96 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/es/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (480.22 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/cs/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (469.25 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/da/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (469.91 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/de/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (467.21 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/et/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (499.01 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/el/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_el.pdf)

français (FR) (467.55 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/fr/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (512.75 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/hr/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (468.92 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/is/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (466.89 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/it/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (481.27 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/lv/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (468.73 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/lt/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (477.71 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/hu/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (479.1 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/mt/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (467.37 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/nl/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (466.47 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/no/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_no.pdf)

polski (PL) (481.66 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/pl/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_pl.pdf)

português (PT) (477.54 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/pt/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_pt.pdf)

română (RO) (468.57 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/ro/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (478.48 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/sk/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (476.63 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/sl/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (466.56 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/fi/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (468.56 KB - PDF)

**First published:**

26/08/2009

**Last updated:**

24/11/2011

[View](/sv/documents/all-authorised-presentations/topotecan-actavis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Topotecan Actavis Active substance topotecan International non-proprietary name (INN) or common name topotecan Therapeutic area (MeSH)

- Uterine Cervical Neoplasms
- Small Cell Lung Carcinoma

Anatomical therapeutic chemical (ATC) code L01CE01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

## Authorisation details

EMA product number EMEA/H/C/001031

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Marketing authorisation issued 24/07/2009 Withdrawal of marketing authorisation 15/01/2019 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Topotecan Actavis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (547.86 KB - PDF)

**First published:** 03/02/2010

**Last updated:** 02/03/2015

[View](/en/documents/procedural-steps-after/topotecan-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Topotecan Actavis : EPAR - Public assessment report

English (EN) (648.62 KB - PDF)

**First published:** 26/08/2009

**Last updated:** 24/03/2010

[View](/en/documents/assessment-report/topotecan-actavis-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Topotecan Actavis

Reference Number: EMEA/CHMP/291093/2009

English (EN) (488.57 KB - PDF)

**First published:** 29/05/2009

**Last updated:** 29/05/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-topotecan-actavis_en.pdf)

**This page was last updated on** 07/03/2019

## Share this page

[Back to top](#main-content)